Diabetes mellitus and abdominal aortic aneurysms: A review of the mechanisms underlying the negative relationship

Diab Vasc Dis Res. 2018 Sep;15(5):367-374. doi: 10.1177/1479164118780799. Epub 2018 Jun 6.

Abstract

Introduction: Diabetes mellitus appears to be negatively associated with abdominal aortic aneurysm; however, the mechanisms underlying this relationship remain poorly understood. The aim of this article is to provide a comprehensive review of the currently understood biological pathways underlying this relationship.

Methods: A review of the literature ('diabetes' OR 'hyperglycaemia' AND 'aneurysm') was performed and relevant studies grouped into biological pathways.

Results: This review identified a number of biological pathways through which diabetes mellitus may limit the presence, growth and rupture of abdominal aortic aneurysms. These include those influencing extracellular matrix volume, extracellular matrix glycation, the formation of advanced glycation end-products, inflammation, oxidative stress and intraluminal thrombus biology. In addition, there is an increasing evidence to suggest that the medications used to treat diabetes can also limit the development and progression of abdominal aortic aneurysms.

Conclusion: The negative association between diabetes and abdominal aortic aneurysm is robust. Future studies should attempt to target the pathways identified in this review to develop novel therapeutic agents aimed at slowing or even halting aneurysm progression.

Keywords: Abdominal aortic aneurysm; diabetes mellitus; hyperglycaemia.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Aorta, Abdominal / drug effects
  • Aorta, Abdominal / metabolism
  • Aorta, Abdominal / pathology*
  • Aortic Aneurysm, Abdominal / blood
  • Aortic Aneurysm, Abdominal / diagnosis
  • Aortic Aneurysm, Abdominal / etiology*
  • Aortic Aneurysm, Abdominal / prevention & control
  • Biomarkers / blood
  • Blood Glucose / metabolism
  • Diabetes Mellitus* / blood
  • Diabetes Mellitus* / diagnosis
  • Diabetes Mellitus* / drug therapy
  • Dilatation, Pathologic
  • Disease Progression
  • Extracellular Matrix / metabolism
  • Glycation End Products, Advanced / blood
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Inflammation Mediators / metabolism
  • Oxidative Stress
  • Risk Factors
  • Vascular Remodeling* / drug effects

Substances

  • Biomarkers
  • Blood Glucose
  • Glycation End Products, Advanced
  • Hypoglycemic Agents
  • Inflammation Mediators